Plasma endocan level and prognosis of immunoglobulin A nephropathy  by Lee, Yu Ho et al.
Kidney Res Clin Pract 35 (2016) 152e159Kidney Research and Clinical Practice
journal homepage: http: / /www.krcp-ksn.com
Contents l ists avai lable at ScienceDirectOriginal ArticlePlasma endocan level and prognosis of immunoglobulin A
nephropathy
Yu Ho Lee, Jin Sug Kim, Se-Yun Kim, Yang Gyun Kim, Ju-Young Moon, Kyung-Hwan Jeong,
Tae Won Lee, Chun-Gyoo Ihm, Sang-Ho Lee*
Division of Nephrology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, KoreaArticle history:
Received 17 March 2016
Received in revised form
4 July 2016
Accepted 5 July 2016
Available online 14 July 2016
Keywords:
Endocan
Endothelial cellespeciﬁc molecule-1
Immunoglobulin A nephropathy* Corresponding author. Division of Nephrolo
Hospital at Gangdong, 892 Dongnam-ro, Gang
Korea.
E-mail address: rulale@dreamwiz.com (S-H Lee
http://dx.doi.org/10.1016/j.krcp.2016.07.001
2211-9132/Copyright © 2016. The Korean Socie
(http://creativecommons.org/licenses/by-nc-ndA B S T R A C T
Background: Endocan, previously called endothelial cellespeciﬁc molecule-1, is a
soluble proteoglycan that is secreted from vascular endothelial cells. Elevated
plasma endocan levels were shown to be associated with poor cardiovascular out-
comes in patients with chronic kidney disease (CKD). We investigated the clinical
relevance of plasma and urine endocan levels in patients with immunoglobulin A
nephropathy (IgAN).
Methods: Sixty-four patients with IgAN and 20 healthy controls were enrolled in
this study. Plasma and urine endocan levels were measured. Clinical parameters,
pathologic grades, and renal outcomes were compared among subgroups with
different plasma and urine endocan levels.
Results: Both plasma and urine endocan levels were signiﬁcantly higher in patients
with IgAN than in controls. Elevated serum phosphorus and C-reactive protein were
independent determinants for plasma endocan, and elevated C-reactive protein was
also an independent determinant for urine endocan levels in multivariate analysis.
Plasma endocan level was not signiﬁcantly different across CKD stages, but patients
with higher plasma endocan levels showed adverse renal outcome. Urine endocan
levels were also elevated in patients with poor renal function. Cox proportional
hazard models showed that high plasma endocan was an independent risk factor for
CKD progression after adjusting for the well-known predictors of outcome in pa-
tients with IgAN.
Conclusion: This study suggested that plasma endocan might be useful as a
prognostic factor in patients with IgAN.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Immunoglobulin A nephropathy (IgAN) is the most common
form of primary glomerulonephritis in Asian countries,gy, Kyung Hee University
dong-gu, Seoul, 134-727,
).
ty of Nephrology. Published b
/4.0/).including Korea [1]. The clinical course and renal prognosis of
patients with IgAN are quite diverse; nevertheless, approxi-
mately 50% of patients eventually progress to end-stage renal
disease, which requires renal replacement therapy within 20
years of the initial diagnosis [2]. Thewell-known risk factors for
poor clinical outcome include elevated serum creatinine levels,
at ﬁrst presentation; sustained hypertension; persistent pro-
teinuria; and speciﬁc pathologic features, including mesangial
hypercellularity; segmental glomerulosclerosis; tubular atro-
phy; and interstitial ﬁbrosis [3,4]. However, none of thesey Elsevier. This is an open access article under the CC BY-NC-ND license
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disease progression remains controversial. Several studies have
described new kidney biomarkers that might predict renal
outcome independently, such as kidney injury molecule-1,
neutrophil gelatinaseeassociated lipocalin, and nestin, but
these markers should be validated more thoroughly [5e7].
Endocan, also known as endothelial cellespeciﬁc molecule-
1, is a 50-kDa proteoglycan that is composed of dermatan sul-
fate and mature polypeptide of 165 amino acids [8]. Unlike
other ubiquitous proteoglycans, which are mainly located in
the connective tissue, endocan is a soluble molecule, secreted
from vascular endothelial cells of various organs, and it can
freely circulate in the blood [9]. The exact role of endocan in
humans remains to be elucidated. However, it has been re-
ported that elevated plasma endocan levels could serve as an
independent risk factor for poor survival in patients with ma-
lignancy, chronic kidney disease (CKD), preeclampsia, sepsis,
and hypertension [10e14].
Several studies have documented endothelial injury in pa-
tients with IgAN by measuring plasma von Willebrand factor
and soluble fmselike tyrosine kinase-1 [15,16]. Given that a key
element in CKD progression is endothelial injury, we hypoth-
esized that endocan could be linked to endothelial dysfunction,
and thus, it may serve as a marker of CKD progression in pa-
tients with IgAN [17]. Currently, no study has investigated
endocan levels in patients with IgAN. The aim of this study was
to evaluate plasma and urine endocan levels in patients with
IgAN to determine whether endocan could serve as a marker of
clinicopathologic severity and prognosis.
Methods
Patient selection and study design
We retrospectively analyzed 64 patients diagnosed with
IgAN based on a renal biopsy, in Kyung Hee University Hospital
at Gangdong from June 2011 to October 2014. The diagnosis of
IgAN was conﬁrmed by an expert pathologist, based on the
following criteria: IgA and/or C3 deposition in the mesangial
area observed with immunoﬂuorescence staining and electron-
dense material deposited in mesangial and paramesangial re-
gions observed with electron microscopy. Other glomer-
ulopathies that mimicked IgAN, such as systemic lupus
erythematosus and HenocheSchonlein purpura as well as
secondary IgAN, were excluded by identifying signs in a careful
patient history and laboratory data. We also excluded patients
who had superimposed acute kidney injury at the time of renal
biopsy. We enrolled 20 additional healthy volunteers; serum
creatinine and fasting glucose levels of those were within
normal range, urinalysis revealed no proteinuria and hematu-
ria, and blood pressure was normal on routine medical
checkup. The Institutional Review Board of Kyung Hee Uni-
versity Hospital at Gangdong approved this study (KHNMC
2008-030). Informed consent was obtained from all patients
and healthy controls.
Age, sex, height, weight, the presence of diabetes, and sys-
tolic and diastolic blood pressures were recorded at the time of
admission. Blood samples were drawn for routine laboratory
analyses in the fasted state, for measuring hemoglobin, total
cholesterol, albumin, creatinine phosphorus, and C-reactive
protein (CRP). The estimated glomerular ﬁltration rate (eGFR)
was calculated with the equation from the Modiﬁcation of Dietin Renal Disease study. Patients were classiﬁed into different
CKD stage groups, according to eGFR. Urine samples were
collected on the morning of the day of renal biopsy. Urine was
evaluated for the presence of hematuria and proteinuria. Pro-
teinuriawas expressed as the urinary protein-to-creatinine ratio
(uPCR), calculated as urinary protein/urinary creatinine (g/gCr).
Collection of plasma and urine samples; measurement of
endocan levels
Additional samples of plasma were collected on the day of
biopsy and stored at e80C. Urine samples were collected in
50-mL sterile conical tubes. After centrifugation of urine for 20
minutes at 2,000g at room temperature, the supernatant was
collected in the tube and kept at a e80C deep freezer. The
enzyme-linked immunosorbent assay method was performed
with a commercial kit (Boster Biological Technology, Pleas-
anton, CA, USA) to measure plasma and urine endocan levels.
Urine creatinine was measured in the same urine specimens.
The urine endocan level was expressed relative to the creati-
nine concentration: endocan/creatinine (pg/gCr).
Histologic grading of IgAN
The pathologic ﬁndings of IgAN were classiﬁed with both
the Oxford classiﬁcation and the modiﬁed H.S. Lee grading
system [18,19]. The 4 pathologic variables of the Oxford clas-
siﬁcation were deﬁned as the following: mesangial hyper-
cellularity  0.5 (M0) or > 0.5 (M1); endocapillary
hypercellularity absent (E0) or present (E1); segmental glo-
merulosclerosis absent (S0) or present (S1); and tubular atro-
phy and/or interstitial ﬁbrosis  25% (T0), 26e50% (T1), and
> 50% (T2). The H.S. Lee system included 5 grades, deﬁned by
the percentage of glomeruli that exhibited crescent/segmental
sclerosis (SS)/global sclerosis (GS). These grades were described
as the following: grade I, normal or focal mesangial cell pro-
liferation; grade II, diffuse mesangial cell proliferation or < 25%
of glomeruli with crescent/SS/GS; grade III, 25e49% of
glomeruli with crescent/SS/GS; grade IV, 50e75% of glomeruli
with crescent/SS/GS; and grade V, > 75% of glomeruli with
crescent/SS/GS.
Treatment of IgAN and follow-up
All patients included in this study visited our outpatient
clinic regularly every 1e3 months. Patients were treated with
an angiotensin-converting enzyme inhibitor (ACEi) or angio-
tensin receptor blocker (ARB) unless proteinuria improved
spontaneously to normal range. Patients who showed persis-
tent proteinuria over 1 g/d despite optimal use of ACEi or ARB
for 3 months received immunosuppressive agents. Routine
laboratory parameters (described previously) were determined
for each visit, and all patients were monitored for CKD pro-
gression and cardiovascular events, including myocardial
infarction, stroke, and death from any cause. CKD progression
was deﬁned as more than 50% reduction in eGFR from the value
observed at the time of biopsy [20,21].
Statistical analysis
Statistical analyses were performed with SPSS for Windows,
version 20.0 (IBM Corp, Armonk, NY, USA), and P values < 0.05
Figure 1. Correlation analysis between plasma endocan and urine
endocan level.
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data are expressed as the mean ± standard deviation or the
number of patients and percentage. Plasma and urine endocan
levels were described as median and interquartile range (IQR)
because these data were nonnormally distributed. Clinical and
laboratory parameters were compared between groups with
the unpaired t test, ManneWhitney U test, or Pearson c2 test as
appropriate. One-way analysis of variance and linear-by-linear
association analyses were used to compare subgroups of pa-
tients with different CKD stages. To assess the determinants of
plasma and urine endocan, we ﬁrst used simple regression
analysis. Subsequently, the Entermethod of multiple regression
analysis was performed with all the univariate associates
(P < 0.1). CKD progression was assessed with the Cox propor-
tional hazard model. We initially performed the Cox analysis
onlywith plasma endocan quartiles. Thereafter, we adjusted for
other variables, as follows: model 1: adjusted for age, gender,
and diabetes; model 2: adjusted for hypertension and eGFR,
plus the variables in model 1; and model 3: adjusted for uPCR
plus the variables in model 2.
We used simple correlation analyses to compare plasma
endocan and urine endocan levels after log transformation of
both endocan levels. Finally, a time-to-event analysis for CKD
progression was performed with a log-rank test.
Results
Plasma and urine endocan levels in patients with IgAN
A total of 64 patients were diagnosed with IgAN (mean age,
44.7 ± 16.1 years; 50% male). The baseline clinical characteris-
tics of patients and healthy controls are shown in Table 1.
Among the patients with IgAN, 6 had diabetes and 27 had hy-
pertension. The mean creatinine level was 1.64 mg/dL, mean
eGFR was 70.42 mL/min/1.73 m2, and mean uPCR was 1.66 g/
gCr. The plasma endocan levels were signiﬁcantly higher in
patients with IgAN than in the control group [198.4 pg/mL (IQR,
109.0e301.6 pg/mL) vs. 111.8 pg/mL (IQR, 35.4e163.7 pg/mL),
P ¼ 0.001]. The urine endocan levels were also higher in pa-
tients with IgAN than in healthy controls [182.6 pg/gCr (IQR,
1.5e909.3 pg/gCr) vs. 0 pg/gCr (IQR, 0e24.2 pg/gCr), P < 0.001].
The urine and plasma endocan levels showed positive rela-
tionship although the correlation coefﬁcient was low (r¼ 0.249
and P ¼ 0.047; Fig. 1). When the patients with IgAN were
grouped according to CKD stages, plasma endocan levels wereTable 1. Baseline clinical characteristics and biochemical parameters of
Variables Control (n ¼ 20)
Age (y) 42.9 ± 12.0
Male 12 (60.0)
BMI (kg/m2) 22.3 ± 2.4
DM 0 (0)
Hypertension 0 (0)
Creatinine (mg/dL) 0.8 ± 0.1
eGFR (mL/min/1.73 m2) 105.3 ± 18.5
uPCR (g/gCr)
Use of ACEi or ARB
Use of immunosuppressive agents
Plasma endocan (pg/mL) 111.8 (35.4e163.7)
Urine endocan (pg/gCr) 0 (0e24.2)
Data are presented as mean ± SD, n (%), or median (interquartile range).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor b
glomerular ﬁltration rate; Ig, immunoglobulin; uPCR, urine protein-to-creatnot different among different CKD stages, but urine endocan
levels were higher in patients with advanced CKD (P ¼ 0.501
and 0.023, respectively; Table 2).
Determinants of plasma and urine endocan levels in patients
with IgAN
Simple logistic regression analyses demonstrated that
serum phosphorus and CRP were positively associated with the
plasma endocan level (Table 3). These variables maintained
positive association with the plasma endocan level in multiple
logistic regression analyses.
The urine endocan level was positively correlated with H.S.
Lee pathologic grades, hemoglobin, serum phosphorus, and
CRP in simple regression analyses. eGFR showed a negative
trend toward signiﬁcance with urine endocan levels, whereas
uPCR showed a positive trend toward signiﬁcance. In multiple
regression analyses, only CRP maintained positive correlation
with the urine endocan level.
Plasma and urine endocan relationships to pathologic
parameters
When patients were grouped according to the H.S. Lee
grading system, both plasma and urine endocan levels werepatients with IgA nephropathy and control group
IgA nephropathy (n ¼ 64) P
44.7 ± 16.1 0.637
32 (50.0) 0.434
23.2 ± 5.4 0.100
6 (9.4) 0.155
27 (42.2) < 0.001
1.6 ± 1.8 < 0.001
70.4 ± 34.7 < 0.001
1.7 ± 2.1
55 (85.9)
18 (28.1)
198.4 (109.0e301.6) 0.001
182.6 (1.5e909.3) < 0.001
locker; BMI, body mass index; DM, diabetes mellitus; eGFR, estimated
inine ratio.
Table 2. Clinical characteristics and biochemical parameters of patients with IgA nephropathy according to CKD stage
Variables CKD stage 1 (n ¼ 22) CKD stage 2 (n ¼ 15) CKD stage 3 (n ¼ 18) CKD stage 4 (n ¼ 9) P
Age (y) 33.8 ± 12.8 43.0 ± 9.7 53.7 ± 16.2 56.3 ± 15.4 < 0.001
Male 9 (40.9) 5 (33.3) 11 (61.1) 7 (77.8) 0.109
DM 2 (9.1) 0 (0) 2 (11.1) 2 (22.2) 0.339
Hypertension 5 (22.7) 3 (20.0) 14 (77.8) 5 (55.6) 0.001
Oxford classiﬁcation
M1 21 (95.5) 10 (66.7) 15 (83.3) 7 (77.8) 0.268
E1 4 (18.2) 4 (26.7) 3 (16.7) 0 (0) 0.294
S1 0 (0) 4 (26.7) 3 (16.7) 3 (33.3) 0.029
T1 1 (4.5) 0 (0) 3 (16.7) 2 (22.2) 0.002
T2 0 (0) 0 (0) 0 (0) 2 (22.2)
H.S. Lee grade
I 1 (4.5) 2 (13.3) 1 (5.6) 0 (0) 0.021
II 9 (40.9) 5 (33.3) 5 (27.8) 1 (11.1)
III 11 (50.0) 7 (46.7) 7 (38.9) 5 (55.6)
IV 1 (4.5) 1 (6.7) 5 (27.8) 3 (33.3)
eGFR (mL/min/1.73 m2) 107.7 ± 16.5 77.0 ± 6.9 46.1 ± 7.3 17.0 ± 10.3 < 0.001
Hemoglobin (g/dL) 13.2 ± 1.4 12.9 ± 1.5 12.6 ± 2.2 10.9 ± 3.0 0.046
Total cholesterol (mg/dL) 185.8 ± 26.7 182.5 ± 35.0 190.2 ± 60.3 192.8 ± 52.8 0.936
Albumin (g/dL) 4.1 ± 0.4 4.0 ± 0.3 3.9 ± 0.5 3.8 ± 0.4 0.100
Phosphorus (mg/dL) 3.4 ± 0.5 3.5 ± 0.4 3.6 ± 0.6 3.9 ± 1.0 0.235
CRP (mg/dL) 0.1 ± 0.1 0.3 ± 0.8 0.6 ± 1.0 0.6 ± 1.3 0.275
uPCR (g/gCr) 0.9 ± 1.0 1.0 ± 0.9 2.3 ± 3.0 3.3 ± 2.5 0.006
Use of ACEi or ARB 18 (81.8) 11 (73.3) 17 (94.4) 9 (100) 0.013
Use of immunosuppressive agents 5 (22.7) 4 (26.7) 8 (44.4) 1 (11.1) 0.784
Plasma endocan (pg/mL) 185.4 (70.8e275.5) 179.9 (70.8e234.5) 261.8 (19.9e375.1) 289.1 (174.5e341.0) 0.501
Urine endocan (pg/gCr) 217.2 (0e939.5) 101.0 (0e337.4) 260.2 (10.5e695.9) 922.1 (0e2380.7) 0.023
Data are presented as mean ± standard deviation, n (%), or median (interquartile range).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; CRP, C-reactive protein; DM, diabetes
mellitus; eGFR, estimated glomerular ﬁltration rate; uPCR, urine protein/creatinine ratio.
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grade IIIþ IV) than in patients with favorable pathologic grades
(H.S. Lee grade Iþ II; Fig. 2). In contrast, there was no signiﬁcant
correlation between Oxford classiﬁcation variables and
plasma and urine endocan levels.
CKD progression in patients with IgAN
Patients with IgAN were followed up for a mean of
25.81 ± 13.29 months. Most patients received an ACEi or ARB
(55/64, 85.9%), and 18 patients (28.1%) were treated with
additional immunosuppressive agents to reduce proteinuria
(Table 1). Patients who exhibited normal or mild decrease inTable 3. Determinants of plasma and urine endocan levels in patients w
Variables Plasma endocan (pg/mL)
Simple regression Enter method o
multiple regressio
Unstandardized
b
SE P Unstandardized
b
SE
Age (y) e0.892 0.686 0.198
DM e42.19 37.82 0.269
Hypertension e14.83 22.46 0.511
H.S. Lee grade 14.30 13.80 0.304
eGFR (mL/min/
1.73 m2)
0.090 0.323 0.278
Hemoglobin (g/dL) e2.645 5.448 0.629
Total cholesterol
(mg/dL)
0.190 0.259 0.466
Albumin (mg/dL) e11.36 28.36 0.690
Phosphorus (mg/dL) 41.43 17.89 0.024 48.44 18.84
CRP (mg/dL) 33.29 13.24 0.015 40.12 14.54
uPCR (g/gCr) 7.998 5.220 0.131
CRP, C-reactive protein; DM, diabetes mellitus; eGFR, estimated glomerular ﬁl
creatinine ratio.eGFR received less ACEi or ARB (Table 2). In contrast, use of
immunosuppressive agents was not different across CKD
stages. No cardiovascular events occurred during follow-up;
however, 8 patients experienced CKD progression.
CKD progression was evaluated with the log-rank test in
patients grouped by plasma and urine endocan levels (Fig. 3).
Patients were divided into quartiles, according to the plasma
endocan level (< 108.99, 108.99e198.42, 198.42e301.59, and
> 301.59 pg/mL), and subsequently divided equally by urine
endocan levels ( 21.14 and > 21.14 pg/gCr). Based on the
plasma endocan level, the rate of reaching CKD progressionwas
signiﬁcantly higher in patients in the fourth quartile than in
patients in the other 3 quartiles (P ¼ 0.003; Fig. 3A). Theith IgA nephropathy
Urine endocan (pg/gCr)
f
n
Simple regression Enter method of
multiple regression
P Unstandardized
b
SE P Unstandardized
b
SE P
5.967 8.967 0.508
e291.5 493.0 0.557
3.743 291.8 0.990
348.5 174.7 0.050 335.2 179.8 0.068
e7.617 4.074 0.066 0.32 4.59 0.944
e174.1 67.11 0.012 e101.0 72.35 0.141
3.573 3.338 0.289
e520.7 361.5 0.155
0.013 489.7 233.2 0.040 380.2 242.6 0.123
0.008 450.1 172.4 0.011 411.1 187.2 0.032
121.6 67.08 0.075 e27.79 77.83 0.722
tration rate; Ig, immunoglobulin; SE, standard error; uPCR, urine protein/
Figure 2. Box-and-whisker plots. Plasma (A) and urine (B) endocan levels
are shown according to H. S. Lee pathologic grading.
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slightly higher in patients with high urine endocan than in
those with low urine endocan (cutoff: 21.14 pg/gCr, median
value), but the difference was not signiﬁcant (P ¼ 0.138;
Fig. 3B).
Cox proportional hazardmodel analyses were performed for
patients with IgAN. We found that plasma endocan in the
highest quartile was an independent risk factor for CKD pro-
gression, after adjusting for baseline clinical characteristics
(model 1) and well-known predictors of outcome (models 2
and 3; Table 4).Discussion
In the present study, we demonstrated that a high plasma
endocan level was an independent risk factor for rapid deteri-
oration of renal function. This ﬁnding was unexpected because
plasma endocan levels were not elevated in patients with IgAN,
and they did not vary signiﬁcantly among patients with
different CKD stages. In contrast, urine endocan was not
signiﬁcantly associated with renal outcome, although it was
elevated in patients with IgAN, and it was correlated with poor
renal function. Poor renal prognosis in patients with high
plasma endocan levels could partly be explained by itscorrelation with pathologic severity. Another explanation for
these ﬁndings could be that high plasma endocan levels might
reﬂect vascular endothelial injury. Some previous studies sup-
ported this hypothesis with demonstrations that endothelial
dysfunction contributed to IgAN pathogenesis and CKD pro-
gression [15e17].
Endocan formation and secretion is a tightly regulated
process. It mainly occurs in the vascular endothelium of lungs
and kidneys [22]. To date, many cytokines and growth factors
are known to affect the level of plasma endocan. Importantly,
tumor necrosis factor-a, interleukin-1b, and lipopolysaccha-
rides strongly upregulated the expression of endocan
messenger RNA [8]. In contrast, interferon-g blocked the effect
of tumor necrosis factor-a on endocan messenger RNA [23]. In
addition, vascular endothelial growth factor, which plays an
important role in the pathogenesis of cancer neoangiogenesis,
was shown to induce endocan expression [24].
Previous studies provided conﬂicting results on the biologic
roles of plasma endocan in the control of inﬂammation. One
experiment with human umbilical vein endothelial cells
demonstrated that elevated endocan could trigger systemic
inﬂammation through the upregulation of vascular cell adhe-
sion molecule-1, intercellular adhesion molecule-1, and E-
selectin [25]. All these molecules can cause leukocyte adhesion
and migration into vascular endothelium. They also observed
increases in the activation of mitogen-activated protein kinase
and nuclear factor-kappa B, which implied that endocan
mediated an inﬂammatory response through a complex
mechanism. In contrast to those ﬁndings, Bechard et al [26]
showed that endocan could bind directly to lymphocyte func-
tioneassociated antigen-1 (LFA-1), a major integrin in human
monocytes and lymphocytes. The interaction between leuko-
cyte LFA-1 and vascular endothelial intercellular adhesion
molecule-1 is a pivotal process in leukocyte adhesion and
migration. Thus, endocan binding to LFA-1 suggested a mech-
anism for the anti-inﬂammatory effect of endocan. It remains to
be clariﬁed whether, in vivo, endocan plays a proinﬂammatory
or anti-inﬂammatory role.
Recently, Yilmaz et al [11] reported a positive correlation
between plasma endocan levels and CKD stages. They sug-
gested that plasma endocan may serve as a predictor of mor-
tality and cardiovascular events. That ﬁnding was not
consistent with our results. We detected no differences in
plasma endocan levels among different CKD stages. This
discrepancy might not only be related to the number of studied
patients and degree of renal dysfunction but also explained by a
difference in the underlying etiologies of CKD. Arman et al [27]
investigated the effects of glycemic regulation on serum
endocan levels in patients with diabetes and found that the
degree of glycemic control could inﬂuence the serum endocan
levels. In the previous study [11], the most common cause of
CKDwas diabetes. Thus, high plasma endocan levels in patients
with advanced CKD might result from poor glycemic control,
rather than the CKD stage. In future studies, the degree of
glycemic control (i.e., hemoglobin A1c) should be assessed to
investigate this possibility.
To our knowledge, this study was the ﬁrst to investigate
urine endocan levels in renal disease. Interestingly, urine
endocan was undetectable in 65% of controls, and the
remaining individuals showed very low levels of urine endocan.
In contrast, most patients with IgAN had variable levels of urine
endocan. These ﬁndings implied that endocan was involved in
Figure 3. Renal outcomes according to plasma (A) and urine (B) endocan levels.
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the negatively charged basement membrane in a healthy
glomerulus can prevent endocan from passing through the
glomerular ﬁltration barrier because of the presence ofTable 4. Cox proportional hazard model for risk of CKD progression
according to plasma endocan quartiles (ﬁrst þ second þ third
quartiles vs. fourth quartile)
Models CKD progression
Hazard ratio
(95% conﬁdence interval)
P
Unadjusted 8.73 (2.01e37.88) 0.004
Adjusted
Model 1 14.48 (2.35e89.27) 0.004
Model 2 16.01 (1.67e154.18) 0.016
Model 3 17.69 (1.78e174.4) 0.014
Model 1 was adjusted for age, gender, and diabetes mellitus.
Model 2 was adjusted for model 1 plus hypertension and estimated
glomerular ﬁltration rate.
Model 3 was adjusted as model 2 plus urine protein/creatinine ratio.
CKD, chronic kidney disease.dermatan sulfate, an important component of endocan, which
is also highly negatively charged [8]. Thus, any glomerular
injury that disrupted the glomerular basement membrane
could permit circulating plasma endocan to leak into the urine.
Alternatively, endocan may leak into the urine from renal tu-
bules. Indeed, immunohistochemistry staining in healthy con-
trol biopsies showed endocan expression in renal tubular
epithelium [9]. In our study, urine endocan levels were not
related to the degree of a tubulointerstitial injury, suggesting
that urine endocan leaked through a disrupted glomerular
barrier, rather than through damaged tubulointerstitial cells.
Because there are scarce data about the metabolism and
excretion of endocan after secretion into blood, thorough in-
vestigations are mandatory to conﬁrm this hypothesis.
The main limitations of this study were the relatively small
numbers of enrolled patients and healthy controls. Also, the
follow-up was relatively short, particularly for evaluations of
clinical events including the occurrence of cardiovascular dis-
ease. Another limitation was that some patients regularly took
medications that might have inﬂuenced endothelial activity at
Kidney Res Clin Pract 35 (2016) 152e159158the time of plasma and urine sampling. Some antihypertensive
agents (e.g., ARBs and calcium channel blockers) and some
lipid-lowering agents are known to reduce plasma endocan
levels [28,29].
In conclusion, our results demonstrated that, among pa-
tients with IgAN, thosewith high plasma endocan levels tended
to show advanced pathologic grades and rapid decline in eGFR.
Further studies are needed to validate whether endocan levels
could serve as a marker of poor renal prognosis.
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